These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24156020)

  • 1. Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine.
    Mortara L; Orecchia P; Castellani P; Borsi L; Carnemolla B; Balza E
    Cancer Med; 2013 Aug; 2(4):478-87. PubMed ID: 24156020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The therapeutic T-cell response induced by tumor delivery of TNF and melphalan is dependent on early triggering of natural killer and dendritic cells.
    Balza E; Zanellato S; Poggi A; Reverberi D; Rubartelli A; Mortara L
    Eur J Immunol; 2017 Apr; 47(4):743-753. PubMed ID: 28198545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan.
    Mortara L; Balza E; Sassi F; Castellani P; Carnemolla B; De Lerma Barbaro A; Fossati S; Tosi G; Accolla RS; Borsi L
    Eur J Immunol; 2007 Dec; 37(12):3381-92. PubMed ID: 18022863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin.
    Balza E; Mortara L; Sassi F; Monteghirfo S; Carnemolla B; Castellani P; Neri D; Accolla RS; Zardi L; Borsi L
    Clin Cancer Res; 2006 Apr; 12(8):2575-82. PubMed ID: 16638868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha.
    Sacchi A; Gasparri A; Gallo-Stampino C; Toma S; Curnis F; Corti A
    Clin Cancer Res; 2006 Jan; 12(1):175-82. PubMed ID: 16397040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. iNOS expression in CD4+ T cells limits Treg induction by repressing TGFβ1: combined iNOS inhibition and Treg depletion unmask endogenous antitumor immunity.
    Jayaraman P; Alfarano MG; Svider PF; Parikh F; Lu G; Kidwai S; Xiong H; Sikora AG
    Clin Cancer Res; 2014 Dec; 20(24):6439-51. PubMed ID: 25278453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model.
    Ko HJ; Kim YJ; Kim YS; Chang WS; Ko SY; Chang SY; Sakaguchi S; Kang CY
    Cancer Res; 2007 Aug; 67(15):7477-86. PubMed ID: 17671218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.
    Liu A; Hu P; Khawli LA; Epstein AL
    Clin Cancer Res; 2005 Dec; 11(23):8492-502. PubMed ID: 16322313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo.
    Tongu M; Harashima N; Monma H; Inao T; Yamada T; Kawauchi H; Harada M
    Cancer Immunol Immunother; 2013 Feb; 62(2):383-91. PubMed ID: 22926062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.
    Suzuki E; Kapoor V; Jassar AS; Kaiser LR; Albelda SM
    Clin Cancer Res; 2005 Sep; 11(18):6713-21. PubMed ID: 16166452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine and checkpoint blockade exhibit synergistic anti-tumor effects in a model of murine lung carcinoma.
    Du B; Wen X; Wang Y; Lin M; Lai J
    Int Immunopharmacol; 2020 Sep; 86():106694. PubMed ID: 32570034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis.
    Ding ZC; Lu X; Yu M; Lemos H; Huang L; Chandler P; Liu K; Walters M; Krasinski A; Mack M; Blazar BR; Mellor AL; Munn DH; Zhou G
    Cancer Res; 2014 Jul; 74(13):3441-53. PubMed ID: 24780756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways.
    Sawant A; Schafer CC; Jin TH; Zmijewski J; Tse HM; Roth J; Sun Z; Siegal GP; Thannickal VJ; Grant SC; Ponnazhagan S; Deshane JS
    Cancer Res; 2013 Nov; 73(22):6609-20. PubMed ID: 24085788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy.
    van der Most RG; Currie AJ; Mahendran S; Prosser A; Darabi A; Robinson BW; Nowak AK; Lake RA
    Cancer Immunol Immunother; 2009 Aug; 58(8):1219-28. PubMed ID: 19052741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine treatment enhanced the anti-tumor effect of cytokine induced killer cells by depletion of CD4
    Zhao P; Zhu D; Zhang Z; Han B; Gao D; Wei X; Xie X; Li C; Sun W; Wang Q; Guo Q
    Immunol Lett; 2017 Jan; 181():36-44. PubMed ID: 27867030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects.
    Zegers CM; Rekers NH; Quaden DH; Lieuwes NG; Yaromina A; Germeraad WT; Wieten L; Biessen EA; Boon L; Neri D; Troost EG; Dubois LJ; Lambin P
    Clin Cancer Res; 2015 Mar; 21(5):1151-60. PubMed ID: 25552483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
    Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA
    Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective targeted delivery of TNFalpha to tumor blood vessels.
    Borsi L; Balza E; Carnemolla B; Sassi F; Castellani P; Berndt A; Kosmehl H; Biro A; Siri A; Orecchia P; Grassi J; Neri D; Zardi L
    Blood; 2003 Dec; 102(13):4384-92. PubMed ID: 12933583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.
    Dijkgraaf EM; Santegoets SJ; Reyners AK; Goedemans R; Nijman HW; van Poelgeest MI; van Erkel AR; Smit VT; Daemen TA; van der Hoeven JJ; Melief CJ; Welters MJ; Kroep JR; van der Burg SH
    Oncotarget; 2015 Oct; 6(31):32228-43. PubMed ID: 26334096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depletion of CD4(+)CD25(high) regulatory T cells from tumor infiltrating lymphocytes predominantly induces Th1 type immune response in vivo which inhibits tumor growth in adoptive immunotherapy.
    Xu L; Xu W; Jiang Z; Zhang F; Chu Y; Xiong S
    Cancer Biol Ther; 2009 Jan; 8(1):66-72. PubMed ID: 19029829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.